Study Finds Plasmodium Falciparum Tolerance to Mefloquine and Piperaquine in Triple Artemisinin-Based Combination Therapy

Researchers have identified a concerning tolerance in Plasmodium falciparum clinical isolates resistant to mefloquine when subjected to a combination treatment involving mefloquine and piperaquine. This finding raises critical questions about the effectiveness of triple artemisinin-based combination therapies (TACTs) in combating malaria. The study highlights potential challenges for global health efforts aimed at controlling the disease, as drug resistance continues to complicate treatment strategies.

The research focused on examining the response of malaria strains to TACTs, which are designed to enhance efficacy by combining multiple antimalarial drugs. However, the study revealed that certain strains of Plasmodium falciparum exhibit resistance not only to mefloquine but also show tolerance when treated with both mefloquine and piperaquine simultaneously. These results suggest that current approaches relying on TACTs may face limitations in regions where drug-resistant malaria strains are prevalent. The findings underscore the need for further investigation into alternative treatment options and strategies to address emerging drug resistance in malaria parasites.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

Related posts:

CDMO Partnerships Streamline Pharma Operations, Accelerate Product Development from Concept to Market Biologics and Biosimilars Offer Distinct Pathways for Treating Autoimmune Diseases and Cancer Study Finds T Cell Reactivity to C9orf72 Peptides Linked to ALS and Neurodegeneration Nickel-Cobalt-Zinc Composite Materials Developed for Non-Enzymatic Glucose Sensors in Medical Diagnostics

Author

GOAI